Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called Nemolizumab for individuals with Atopic Dermatitis, which is a chronic skin condition that causes itchy and inflamed skin. The treatment involves using a solution for injection, which is administered under the skin. The study aims to understand how safe Nemolizumab is for people with moderate-to-severe atopic dermatitis over an extended period.

Participants in the study will receive Nemolizumab, which is also known by its code name CD14152 or CIM331. Some participants may receive a placebo. The study will monitor participants over a long duration to observe any side effects and to assess how well the treatment works in reducing the symptoms of atopic dermatitis. The study will also evaluate the impact of the treatment on the quality of life of the participants.

Throughout the study, participants will have regular visits to track their progress and any changes in their condition. The study will collect information on the severity of the skin condition, the level of itchiness, and any improvements in sleep and daily activities. The goal is to gather comprehensive data on the safety and benefits of Nemolizumab for managing atopic dermatitis.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be assessed to ensure they meet the eligibility criteria. This includes having moderate-to-severe atopic dermatitis and a history of inadequate response to topical treatments.

    The patient must agree to apply a moisturizer daily and use authorized topical therapy as needed.

  2. Step 2

    Initial treatment phase

    The patient will begin treatment with nemolizumab, administered as a solution for injection under the skin (subcutaneous use).

    The dosage and frequency of administration will be determined by the study protocol and the healthcare provider overseeing the trial.

  3. Step 3

    Ongoing treatment and monitoring

    Throughout the study, the patient will receive regular injections of nemolizumab and attend scheduled visits to monitor the safety and effectiveness of the treatment.

    The patient will be evaluated for any side effects or adverse events, and their atopic dermatitis symptoms will be assessed using various scales and questionnaires.

  4. Step 4

    Long-term follow-up

    The study is designed to assess the long-term safety and efficacy of nemolizumab over a period that may extend up to 200 weeks.

    During this time, the patient will continue to receive treatment and attend follow-up visits as outlined in the study schedule.

  5. Step 5

    Completion of the study

    Upon completion of the study, the patient's overall response to the treatment will be evaluated.

    The patient will be informed about the outcomes and any further steps, if necessary, based on their individual health needs.

Who can join the trial?

12 criteria

  • Adolescents aged 12-17 who have not participated in a previous study with the medication **Nemolizumab** or those who may benefit from the study, as determined by the study doctor.
  • Participants must have **atopic dermatitis** affecting at least 10% of their body surface area.
  • Participants must have a **SCORAD pruritus VAS score** of at least 4.0, which measures itchiness on a scale from 0 to 10.
  • Participants must have a recent history of not responding well to topical medications, which are creams or ointments applied to the skin.
  • Participants must agree to apply a moisturizer at least once daily and use the approved topical therapy as directed by the study doctor.
  • Women who can have children must agree to use an effective method of birth control or practice true abstinence during the study and for 12 weeks after the last study drug injection.
  • Women who cannot have children must meet specific criteria, such as not having menstrual periods for 1 year or having had certain surgeries.
  • Participants and their guardians, if applicable, must be willing and able to follow all study requirements and schedules.
  • Participants and their guardians, if applicable, must understand and sign a consent form before any study procedures are done.
  • Participants must have had **chronic atopic dermatitis** for at least 2 years, confirmed by specific criteria.
  • Participants must have an **EASI score** of at least 16, which measures the severity of eczema.
  • Participants must have an **IGA score** of at least 3, which indicates moderate to severe eczema.

Who cannot join the trial?

9 criteria

  • Patients who have a history of severe allergic reactions to any of the ingredients in the study medication.
  • Individuals with other skin conditions that might interfere with the study, such as psoriasis or eczema not related to atopic dermatitis.
  • Participants who have used certain medications that could affect the study results, like strong steroids or immunosuppressants, within a specific time before the study starts.
  • People with a history of certain infections, such as tuberculosis, or those who have tested positive for certain viruses like HIV or hepatitis.
  • Women who are pregnant or breastfeeding, as the effects of the study medication on unborn babies or infants are not known.
  • Individuals with a history of drug or alcohol abuse, as this could affect their ability to follow the study procedures.
  • Patients with certain medical conditions that could make participation unsafe, such as severe heart, liver, or kidney disease.
  • Anyone who has participated in another clinical trial within a certain period before this study, to avoid interference with the results.
  • Individuals who are unable to comply with the study requirements, such as attending regular visits or following the treatment plan.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Nemolizumab (CD14152) is a medication being studied for its safety and effectiveness in treating moderate-to-severe atopic dermatitis, a type of eczema that causes itchy and inflamed skin. This trial aims to understand how well Nemolizumab works over a long period and to ensure it is safe for use in adults and adolescents with this skin condition.

What is already known about the treatment

Nemolizumab – Nemolizumab is administered as an injection under the skin, typically in a healthcare setting. It is currently being studied in clinical trials to evaluate its long-term safety and effectiveness for treating moderate-to-severe atopic dermatitis, a chronic skin condition. The medication works by targeting and blocking a specific protein involved in the inflammatory process, which helps reduce symptoms like itching and skin inflammation. Nemolizumab is classified as a monoclonal antibody, a type of medication designed to interact with specific molecules in the body to alter disease processes.

Investigated diseases

Atopic Dermatitis – Atopic dermatitis is a chronic skin condition characterized by dry, itchy, and inflamed skin. It often begins in childhood but can occur at any age. The skin may become red, swollen, and cracked, and in some cases, blisters may form. The condition tends to flare periodically and then subside. It is commonly associated with other allergic conditions like asthma and hay fever. The exact cause is unknown, but it is believed to involve a combination of genetic and environmental factors.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-514404-13-00Protocol codeRD.06.SPR.118163Estimated enrolment1 903 patientsSponsorGalderma S.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.